First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
Running, not enrolling · Early Phase 1
Conditions studied: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Metastatic Malignant Neoplasm in the Breast, Metastatic Malignant Neoplasm in the Colon, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Rectum, Pancreatic Carcinoma
In brief
This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.
Key facts
- Study ID
- NCT03164486
- Run by
- Julie L. Sutcliffe, Ph.D
- People needed
- 27
- Starts
- 2016-11-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-02-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreas
- Eastern Cooperative Oncology Group (ECOG) performance score of 0-1
- Will sign the Institutional Review Board (IRB)-approved consent form
- Able to remain motionless for up to 30-60 minutes per scan
You may not qualify if…
- Creatinine > 2 x upper limit of normal
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x upper limit of normal
- Life expectancy < 3 months (mo)
- Women who are pregnant or breast-feeding
- Patients who cannot undergo PET/compute tomography (CT) scanning
- Lack of availability for follow-up assessments
- Participation in another clinical trial involving an investigational agent within 4 weeks of enrollment
Where it is running
- University of California Davis Comprehensive Cancer Center — Sacramento, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.